Sanara MedTech Inc. (SMTI)Healthcare | Medical Instruments & Supplies | Fort Worth, United States | NasdaqCM
34.57 USD
-0.01
(-0.029%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 34.57 |
Hot Take ↕ | Aug. 22, 2026, 5:30 a.m. EDT
The immediate investment thesis is entirely driven by the confirmed acquisition agreement where MiMedx agreed to purchase the company at $35 per share in a cash-and-stock merger. With the current trading price hovering just below this target, the stock offers a compelling near-term catalyst as the market prices in the certainty of the exit. The recent price action reflects this, with the stock trading in a tight range near the deal price, suggesting high conviction among traders anticipating the closing mechanics. However, looking beyond the takeover premium reveals a fundamentally distressed business; the company is reporting negative profit margins and negative return on equity, indicating that the core operations are not generating sustainable value on their own. Furthermore, there is no dividend history to speak of, offering zero income support for investors who might be tempted by the headline numbers. While the acquisition provides a clear path to liquidity and likely a significant return for holders, the underlying enterprise lacks the operational resilience to stand alone, making this a speculative play on the deal rather than a fundamental investment in the company's future. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.096759 |
| AutoETS | 0.096763 |
| AutoTheta | 0.098403 |
| MSTL | 0.099665 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 28% |
| H-stat | 18.38 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 1.58 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 611.633 |
| Revenue per Share | 12.632 |
| Market Cap | 317,630,368 |
| Forward P/E | 64.02 |
| Beta | 1.16 |
| Profit Margins | -29.15% |
| Website | https://sanaramedtech.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.0017325878 |
| Address1 | 1,200 Summit Avenue |
| Address2 | Suite 414 |
| All Time High | 7,800.0 |
| All Time Low | 2.0 |
| Ask | 34.57 |
| Ask Size | 1 |
| Audit Risk | 7 |
| Average Analyst Rating | 3.0 - Hold |
| Average Daily Volume10 Day | 311,050 |
| Average Daily Volume3 Month | 213,890 |
| Average Volume | 213,890 |
| Average Volume10Days | 311,050 |
| Beta | 1.158 |
| Bid | 24.77 |
| Bid Size | 2 |
| Board Risk | 6 |
| Book Value | 0.767 |
| City | Fort Worth |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 7 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 34.57 |
| Current Ratio | 2.577 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 34.76 |
| Day Low | 34.46 |
| Debt To Equity | 611.633 |
| Display Name | Sanara MedTech |
| Dividend Date | 1,557,446,400 |
| Earnings Call Timestamp End | 1,778,587,200 |
| Earnings Call Timestamp Start | 1,778,587,200 |
| Earnings Timestamp End | 1,794,427,200 |
| Earnings Timestamp Start | 1,794,427,200 |
| Ebitda | 12,745,435 |
| Ebitda Margins | 0.116059996 |
| Enterprise To Ebitda | 27.518 |
| Enterprise To Revenue | 3.194 |
| Enterprise Value | 350,729,952 |
| Eps Current Year | 0.2 |
| Eps Forward | 0.54 |
| Eps Trailing Twelve Months | -0.04 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 28.8228 |
| Fifty Day Average Change | 5.7472 |
| Fifty Day Average Change Percent | 0.1993977 |
| Fifty Two Week Change Percent | -0.17325878 |
| Fifty Two Week High | 35.95 |
| Fifty Two Week High Change | -1.3800011 |
| Fifty Two Week High Change Percent | -0.038386676 |
| Fifty Two Week Low | 16.05 |
| Fifty Two Week Low Change | 18.52 |
| Fifty Two Week Low Change Percent | 1.1538942 |
| Fifty Two Week Range | 16.05 - 35.95 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 765,725,400,000 |
| Float Shares | 3,761,398 |
| Forward Eps | 0.54 |
| Forward P E | 64.01852 |
| Free Cashflow | 5,698,835 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 108 |
| Fullday Change | -0.0100021 |
| Fullday Change Percent | -0.0289246 |
| Fullday Price | 34.57 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.9303 |
| Gross Profits | 102,161,272 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.47974998 |
| Held Percent Institutions | 0.19747 |
| Implied Shares Outstanding | 9,188,035 |
| Industry | Medical Instruments & Supplies |
| Industry Disp | Medical Instruments & Supplies |
| Industry Key | medical-instruments-supplies |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,557,446,400 |
| Last Split Factor | 1:100 |
| Long Business Summary | Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical solutions to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns. It also develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY Tissue Repair Graft(FORTIFY TRG), a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; BiFORM, an osteoconductive, bioactive, porous implant that allows bony ingrowth across the graft site and it can be used as a strip or molded into a putty to fill a bone defect; ACTIGEN Inductive Bone Matrix, a naturally derived, differentiated allograft matrix with robust handling properties; ALLOCYTE Plus, a human allograft cellular bone matrix containing bone-derived progenitor cells and conformable bone fibers; and TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement. The company has a license agreement with Rochal to develop, market, and sell antimicrobial products that include BIASURGE Advanced Surgical Solution, BIAKOS Antimicrobial Wound Gel, and BIAKOS Antimicrobial Skin and Wound Cleanser for the prevention and treatment of microbes on the human body. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas. |
| Long Name | Sanara MedTech Inc. |
| Market | us_market |
| Market Cap | 317,630,368 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_944412 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -284,721 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 317,722,250 |
| Number Of Analyst Opinions | 3 |
| Open | 34.46 |
| Operating Cashflow | 5,694,567 |
| Operating Margins | 0.06328 |
| Overall Risk | 6 |
| Payout Ratio | 0.0 |
| Phone | 817 529 2300 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 34.57 |
| Post Market Time | 1,787,959,805 |
| Previous Close | 34.58 |
| Price Eps Current Year | 172.84999 |
| Price Hint | 2 |
| Price To Book | 45.071705 |
| Price To Sales Trailing12 Months | 2.8924153 |
| Profit Margins | -0.29154 |
| Quick Ratio | 2.241 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | hold |
| Recommendation Mean | 3.0 |
| Region | US |
| Regular Market Change | -0.0100021 |
| Regular Market Change Percent | -0.0289246 |
| Regular Market Day High | 34.76 |
| Regular Market Day Low | 34.46 |
| Regular Market Day Range | 34.46 - 34.76 |
| Regular Market Open | 34.46 |
| Regular Market Previous Close | 34.58 |
| Regular Market Price | 34.57 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 344,469 |
| Return On Assets | 0.07638 |
| Return On Equity | -0.01321 |
| Revenue Growth | 0.09 |
| Revenue Per Share | 12.632 |
| Sand P52 Week Change | 0.20204377 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 6 |
| Shares Outstanding | 9,188,035 |
| Shares Percent Shares Out | 0.023 |
| Shares Short | 211,128 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 377,539 |
| Short Name | Sanara MedTech Inc. |
| Short Percent Of Float | 0.0395 |
| Short Ratio | 0.59 |
| Source Interval | 15 |
| State | TX |
| Symbol | SMTI |
| Target High Price | 35.0 |
| Target Low Price | 35.0 |
| Target Mean Price | 35.0 |
| Target Median Price | 35.0 |
| Total Cash | 15,421,170 |
| Total Cash Per Share | 1.678 |
| Total Debt | 48,529,768 |
| Total Revenue | 109,814,928 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.04 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 22.9188 |
| Two Hundred Day Average Change | 11.651199 |
| Two Hundred Day Average Change Percent | 0.5083686 |
| Type Disp | Equity |
| Volume | 344,469 |
| Website | https://sanaramedtech.com |
| Zip | 76,102 |